Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014378 · ClinicalTrials.gov registry record · Phase 1
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00014378: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00014378 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014378, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: The Chinese herb Huang Lian contains ingredients that may slow the growth of cancer cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of Huang Lian in treating patients who have advanced solid tumors.
Interventions
- DRUG Chinese Herb Huanglian (Coptis chinesis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2000-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014378
The ClinicalTrials.gov registry entry for NCT00014378 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chinese Herb Huanglian (Coptis chinesis) is the first listed.
NCT00014378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014378 about?
NCT00014378 is a clinical study titled "Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors". RATIONALE: The Chinese herb Huang Lian contains ingredients that may slow the growth of cancer cells and may be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of Huang Lian in treating patients who have advanced solid tumors.
What is the current status of trial NCT00014378?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2000-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00014378?
The interventions under investigation include: Chinese Herb Huanglian (Coptis chinesis) (DRUG).
Who is sponsoring clinical trial NCT00014378?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.